Elranatamab

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Elranatamab, sold under the brand name Elrexfio, is a medication used for the treatment of multiple myeloma. Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. Elranatamab is given by subcutaneous injection. The most common side effects include cytokine release syndrome, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and pyrexia (fever). Elranatamab was approved for medical use in the United States in August 2023, in the European Union in December 2023, and in Canada in December 2023.

Elranatamab, sold under the brand name Elrexfio, is a medication used for the treatment of multiple myeloma. Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. Elranatamab is given by subcutaneous injection. The most common side effects include cytokine release syndrome, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and pyrexia (fever). Elranatamab was approved for medical use in the United States in August 2023, in the European Union in December 2023, and in Canada in December 2023.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1364136044 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

13 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.